Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IONIS FB LRx

Next Previous
Search
Drug Profile

IONIS FB LRx

Alternative Names: RO-7434656; ASO Factor B; IONIS-FB-LRx; IONIS-FB-LRX; ISIS-696844; RG-6299; Sefaxersen

Latest Information Update: 16 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ionis Pharmaceuticals
  • Developer Ionis Pharmaceuticals; Roche
  • Class Antisense oligonucleotides; Eye disorder therapies
  • Mechanism of Action Complement factor B expression inhibitors; Gene silencing
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III IgA nephropathy
  • Discontinued Age-related macular degeneration

Most Recent Events

  • 16 Aug 2024 Discontinued - Phase-II for Age-related macular degeneration (In the elderly, In adults) in Spain, Poland, Netherlands, Czech Republic, Canada, Austria, New Zealand, USA, Australia (SC) (Roche pipeline, August 2024)
  • 12 Jun 2024 Ionis Pharmaceuticals completes the phase II GOLDEN trial in Age-related macular degeneration in USA, Australia, Austria, Canada, Czech Republic, Netherlands, New Zealand, Poland and Spain (SC) (NCT03815825)
  • 09 May 2024 Roche plans to file regulatory filing for IgA nephropathy, in or after 2027 (Roche pipeline, May 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top